Experimental drug targets Hard-to-Treat neuroendocrine cancers

NCT ID NCT07684170

Not yet recruiting Disease control Sponsor: Compass Therapeutics Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial tests an experimental drug called CTX-471 in people with advanced neuroendocrine tumors that have a specific marker (NCAM) and have stopped responding to standard treatments. Participants receive the drug by IV every two weeks. The study aims to see if the drug can shrink tumors and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CTX-471
What this could lead to: If successful, this could provide a new treatment option for people with advanced neuroendocrine tumors that have stopped responding to standard therapies.
What could go wrong: This is an early phase 2 trial with a small number of participants, so results may not confirm effectiveness. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE CARCINOMAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE CARCINOMAS NEUROENDOCRINE NEOPLASM NEUROENDOCRINE TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.